Stocks Health care AXGN
NASDAQ · Health careAxogen, Inc. (AXGN)
Axogen, Inc. brought in $266.9M of revenue over the twelve months to September 30, 2026, up 24.3% from a year earlier. It posted a net loss of $31.9M. In fiscal 2025 capital spending exceeded operating cash flow by $2.9M. At September 30, 2026 it held $328.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 28, 2026.
Key facts about Axogen, Inc.
- Net worth
- Axogen, Inc. has a market value (market cap) of $2.7B at the latest share price, and shareholders' equity of $496.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $225.2M (+20.2% year on year), with a net loss of $15.7M. Over the 12 months to September 30, 2026: revenue $266.9M, net loss $31.9M.
- Cash flow
- In fiscal 2025 operations brought in $812K of cash; after $3.7M of capital spending, free cash flow was -$2.9M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 28, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Axogen, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Axogen, Inc. does
Axogen, Inc. is registered with the SEC under industry code SIC 3845 (Electromedical & Electrotherapeutic Apparatus). Its shares trade on NASDAQ under the ticker AXGN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $225.2M | -$15.7M | -$0.34 | -$2.9M |
| 2024 | $187.3M | -$10M | -$0.23 | $1.4M |
| 2023 | $159M | -$21.7M | -$0.51 | -$19.6M |
| 2022 | $138.6M | -$28.9M | -$0.69 | -$36.1M |
| 2021 | $127.4M | -$27M | -$0.65 | -$41.2M |
| 2020 | $112.3M | -$23.8M | -$0.60 | -$31.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where AXGN ranks in Health care
Latest SEC filings
What Axogen, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- October 28, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 26% to $75.8M versus the same quarter last year; diluted EPS $0.04 versus $0.01.
- October 28, 2026
- October 2, 2026Passive stake (5% or more) SCHEDULE 13G
- October 1, 2026
- September 10, 2026Material agreement 8-K/A
- September 10, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- July 31, 2026Passive stake changed SCHEDULE 13G/A
- July 29, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 23% to $69.7M versus the same quarter last year; diluted EPS -$0.03 versus $0.01.
Insider trades
What the people running Axogen, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $173.9K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 2, 2026 | Tyndall Joseph A.Director | Soldpre-planned (10b5-1) | 3,500 | $173.9K |
| August 11, 2026 | Wendell Amy McBrideDirector | Exercised options | 13,353 | $198.3K |
| August 11, 2026 | Wendell Amy McBrideDirector | Soldpre-planned (10b5-1) | 13,353 | $646.6K |
| August 10, 2026 | Began Marc AEVP & General Counsel | Exercised options | 67,500 | $550.8K |
| August 10, 2026 | Began Marc AEVP & General Counsel | Soldpre-planned (10b5-1) | 67,500 | $3.2M |
| August 7, 2026 | Weiler Kathy JohnsonDirector | Soldpre-planned (10b5-1) | 14,150 | $641K |
| June 19, 2026 | Burke William P. Mr.Director | Exercised options | 14,150 | - |
| June 19, 2026 | Tyndall Joseph A.Director | Exercised options | 14,150 | - |
Who owns AXGN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Mathew P. Arens13G, passive with 1 related filers | 7.58% | August 14, 2026 |
| Divisadero Street Capital Management, LP13G, passive with 4 related filers | 6.8% | October 2, 2026 |
| Morgan Stanley13G, passive with 1 related filers | 5.3% | February 3, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 253 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 4,419,208 | +548,357 |
| First Light Asset Management, LLC | 2,748,361 | -1,254,407 |
| Morgan Stanley | 2,747,924 | -375,058 |
| Vanguard Capital Management LLC | 2,257,948 | -33,615 |
| Assenagon Asset Management S.A. | 2,087,300 | +706,037 |
| Polar Capital Holdings Plc | 1,500,822 | 0 |
| Artemis Investment Management LLP | 1,396,792 | +1,046,904 |
| Wellington Management Group Llp | 1,391,654 | +427,089 |
| Geode Capital Management, LLC | 1,375,240 | +155,099 |
| Citadel Advisors LLC | 1,360,831 | +1,115,777 |
| Wasatch Advisors LP | 1,295,949 | -561,401 |
| Goldman Sachs Group Inc | 1,261,519 | +678,556 |
| State Street Corp | 1,246,821 | +100,318 |
| Fmr LLC | 1,222,864 | -91,156 |
| Hood River Capital Management LLC | 1,067,072 | new |
| Rtw Investments, LP | 1,011,576 | new |
| Next Century Growth Investors LLC | 872,546 | +6,583 |
| UBS Group AG | 836,209 | +721,989 |
| Armistice Capital, LLC | 775,000 | -161,000 |
| Bamco Inc | 740,210 | +96,467 |
Insiders
12 insiders reported holding 836,780 shares in total, about $42.3M at the last price.
| Holder | Shares |
|---|---|
| DeVinney Erick WayneChief Innovation Officer | 262,781 |
| Wendell Amy McBrideDirector | 107,976 |
| Quackenbush DorisSales VP | 92,416 |
| Kemp JensChief Marketing Officer | 72,451 |
| Hartley Lindsey MarieCFO | 65,146 |
| Dale Michael DChief Executive Officer | 63,537 |
| Levine Alan MDirector | 50,893 |
| Began Marc AEVP & General Counsel | 50,135 |
| Thomas PaulDirector | 32,395 |
| Burke William P. Mr.Director | 14,250 |
Questions about AXGN
What does Axogen, Inc. do?
Axogen, Inc. is a company in the Health care sector, listed on NASDAQ as AXGN. Its shares trade on NASDAQ under the ticker AXGN.
What is Axogen, Inc.'s net worth?
Axogen, Inc. has a market value (market cap) of $2.7B at the latest share price, and shareholders' equity of $496.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Axogen, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $31.9M on revenue of $266.9M.
How much revenue does Axogen, Inc. make?
Over the twelve months to September 30, 2026 Axogen, Inc. reported revenue of $266.9M. That is 24.3% more than a year earlier.
When did Axogen, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 28, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the investor disclosure from November 9, 2026.
When is Axogen, Inc.'s next earnings report?
Axogen, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare AXGN with
Follow AXGN
Get an email when Axogen, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Axogen, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.